Skip to main content

Table 1 Baseline characteristics of the study patients

From: Clinical benefits and risks of anticoagulation therapy according to the degree of chronic kidney disease in patients with atrial fibrillation

CKD Grade

1

2

3

4

5

p

(n = 3096)

(n = 5420)

(n = 3338)

(n = 482)

(n = 378)

 

Age (years)

55 (47, 62)

65 (59, 71)

74 (69, 78)

77 (69, 83)

66 (58, 74)

< 0.001

Male

2366 (76.4)

3676 (67.8)

1820 (54.5)

233 (48.3)

212 (56.1)

< 0.001

Body mass index

25.8 (23.9, 28.1)

24.5 (22.7, 26.3)

23.2 (21.0, 25.2)

22.5 (20.2, 24.9)

22.8 (20.6, 25.1)

< 0.001

Hypertension

1796 (58.0)

3542 (65.4)

2568 (76.9)

407 (84.4)

351 (92.9)

< 0.001

Diabetes

438 (14.1)

869 (16.0)

778 (23.3)

214 (44.4)

210 (55.6)

< 0.001

Vascular disease

82 (2.6)

244 (4.5)

249 (7.5)

59 (12.2)

54 (14.3)

< 0.001

History of heart failure

279 (9.0)

575 (10.6)

640 (19.2)

154 (32.0)

106 (28.0)

< 0.001

Previous ischemic stroke

229 (7.4)

555 (10.2)

483 (14.5)

72 (14.9)

54 (14.3)

< 0.001

Previous ICH

36 (1.2)

75 (1.4)

59 (1.8)

11 (2.3)

12 (3.2)

0.009

CHA2DS2-VASc score

1 (0, 2)

2 (1, 3)

3 (2,4)

4 (3, 5)

3 (2, 5)

< 0.001

HAS-BLED score

1 (1, 2)

2 (1, 2)

2 (1, 3)

2 (2, 3)

3 (2, 4)

< 0.001

Paroxysmal AF

1811 (58.5)

2597 (47.9)

1345 (40.3)

207 (42.9)

223 (59.0)

< 0.001

History of malignancy

597 (19.3)

1421 (26.2)

970 (29.1)

124 (25.7)

85 (22.5)

< 0.001

LVEF

59 (54, 64)

59 (54, 63)

58 (50, 62)

57 (46, 62)

57 (46, 62)

< 0.001

LA A-P diameter

43 (38, 48)

44 (39, 49)

45 (39, 50)

44 (39, 50)

45 (41, 50)

< 0.001

  1. Data are presented as the median (interquartile range) or number (%)
  2. ICH: Intracranial haemorrhage, LVEF: Left ventricular ejection fraction, LVEDD: Left ventricular end-diastolic dimension, LA A-P: Left atrial anterior–posterior